What is claimed is:

1. An isolated polypeptide comprising the mature form of an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 71 or is 94.

2. A composition comprising the polypeptide of claim 1 and a carrier.

3. A kit comprising, in one or more containers, the composition of claim 2.

4. A method for determining the presence or amount of the polypeptide of claim 1 in a sample, the method comprising:
   (a) providing the sample;
   (b) introducing the sample to an antibody that binds immunospecifically to the polypeptide; and
   (c) determining the presence or amount of the antibody bound to the polypeptide,
   wherein the presence or amount of the antibody indicates the presence or amount of the polypeptide in the sample.

5. A method for determining the presence of or predisposition to a disease associated with altered levels of expression of the polypeptide of claim 1 in a first mammalian subject, the method comprising:
   a) measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and
   b) comparing the expression of the polypeptide in the sample of step (a) to the expression of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to the disease,
   wherein an alteration in the level of expression of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

6. A method of identifying an agent that binds to the polypeptide of claim 1, the method comprising:
   (a) introducing the polypeptide to the agent; and
   (b) determining whether the agent binds to the polypeptide.

7. The method of claim 6 wherein the agent is a cellular receptor or a downstream effector.

8. A method for identifying a potential therapeutic agent for use in treatment of a pathology, wherein the pathology is related to aberrant expression or aberrant physiological interactions of the polypeptide of claim 1, the method comprising:

    (a) providing a cell expressing the polypeptide of claim 1 and having a property or function ascribable to the polypeptide;

    (b) contacting the cell with a composition comprising a candidate substance; and

    (c) determining whether the substance alters the property or function ascribable to the polypeptide;

    whereby, if an alteration observed in the presence of the substance is not observed when the cell is contacted with a composition in the absence of the substance, the substance is identified as a potential therapeutic agent.

9. A method for screening for a modulator of activity of or of latency or predisposition to a pathology associated with the polypeptide of claim 1, the method comprising:

    (a) administering a test compound to a test animal at increased risk for a pathology associated with the polypeptide of claim 1, wherein the test animal recombinantly expresses the polypeptide of claim 1;

    (b) measuring the activity of the polypeptide in the test animal after administering the compound of step (a); and

    (c) comparing the activity of the polypeptide in the test animal with the activity of the polypeptide in a control animal not administered the compound, wherein a change in the activity of the polypeptide in the test animal relative to the control animal indicates the test compound is a modulator of activity of or latency or predisposition to, a pathology associated with the polypeptide of claim 1.

10. The method of claim 9, wherein said test animal is a recombinant test animal that expresses the polypeptide as a transgene or expresses the transgene under the control of a promoter at an increased level relative to a wild-type test animal, and wherein the promoter is not the native gene promoter of the transgene.

11. An antibody that immunospecifically binds to the polypeptide of claim 1.

12. The antibody of claim 11, wherein the antibody is a human monoclonal antibody.

13. A method of producing the polypeptide of claim 1, the method comprising culturing a cell under conditions that lead to expression of the polypeptide, wherein said cell comprises a vector comprising an isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 71.

14. The method of claim 13 wherein the cell is chosen from the group comprising a bacterial cell, an insect cell, a yeast cell and a mammalian cell.

15. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 71 or is 94.

16. A method of treating a pathological state in a mammal, the method comprising administering to the mammal a polypeptide in an amount that is sufficient to alleviate the pathological state, wherein the polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 71 or is 94, or a biologically active fragment thereof.

17. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 71.

18. An isolated nucleic acid molecule encoding the mature form of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 71 or is 94.

19. A vector comprising the nucleic acid molecule of claim 18.

20. A cell comprising the vector of claim 19.